DUPILUMAB EFFICACY AND SAFETY IN ADULT AND ADOLESCENT PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM PART A OF A RANDOMIZED, PLACEBO-CONTROLLED THREE-PART, PHASE 3 STUDY

Evan S. Dellon  ¹     Marc E. Rothenberg  ²     Margaret H. Collins  ²     Ikuo Hirano  ³     Mirna Chehade  ⁴     Arjan Bredenoord  ⁵     Alfredo J. Lucendo  ⁶     Jonathan Spergel  ⁷     Qiong Zhao  ⁸     Jennifer D. Hamilton  ⁸     Bethany Beazley  ⁸     Isabelle Guillemin  ⁹     Siddhesh Kamat  ⁹     Leda Mannent  ⁹     Marcella Ruddy  ⁹     Elizabeth Laws  ¹⁰     Bolanle Akinlade  ¹⁰     Nikhil Amin  ¹⁰     Allen Radin  ¹⁰     Brad *Shumel  ¹⁰     Jennifer *Maloney  ^10    
1 University of North Carolina School of Medicine, Chapel Hill, NC, United States
² Cincinnati Children’s Hospital Medical Center and University of Cincinnati College of Medicine, Cincinnati, OH, United States
³ Northwestern University Feinberg School of Medicine, Chicago, IL, United States
⁴ Mount Sinai Center for Eosinophilic Disorders, Icahn School of Medicine at Mount Sinai, New York, NY, United States
⁵ Amsterdam University Medical Center, Amsterdam, Netherlands
⁶ Hospital General de Tomelloso, Tomelloso, Spain
⁷ Children's Hospital of Philadelphia, Philadelphia, PA, United States
⁸ Regeneron Pharmaceuticals, Inc., Tarrytown, NY, United States
⁹ Sanofi, Chilly-Mazarin, France
¹⁰ Sanofi, Bridgewater, NJ, United States

Topic
IBD

Session
Late breaking abstracts: GI inflammation and infection - From IBD to eosinophilic oesophagitis

Conference
UEG Week Virtual 2020

Citation
United European Gastroenterology Journal 2020; 8 (Supplement 1)